domingo, 8 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 11, 2026

Stock market today: Dow, S&P 500, Nasdaq end little changed as strong jobs report complicates Fed's rate path

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq end little changed as strong jobs report complicates Fed's rate path US stocks were little changed on Wednesday, as investors digested a January jobs report that blew past expectations on a monthly basis…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The January jobs report is the 'Super Bowl of jobs reports'.

    80% confidence
  • There is a 94.1% probability that the Fed will keep rates in their current range of 3.5%-3.75% at the March meeting, up from 79.9% a day prior.

    80% confidence
  • Kraft Heinz's challenges are fixable and within the company's control, and the $600 million investment will accelerate return to profitable growth.

    80% confidence
  • Vertiv expects momentum to continue in 2026 with record backlog providing clear visibility into another year of significant growth.

    80% confidence
  • Smaller job gains in the labor market may be explained by a productivity boom.

    80% confidence
  • President Trump said he is thinking about sending a second US aircraft carrier to Middle Eastern waters.

    80% confidence
  • Economists characterized the jobs report release day with skepticism, calling it #ConspiracyTheoryJobsday.

    80% confidence
  • Ship captains should remain as far as possible from Iran's territorial sea without compromising navigational safety.

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,996
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,996 factos verificados com a fonte5,552 documentos-fonte arquivados
Consulte estes dados → isubstrate.com